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ABSTRACT: DNA topoisomerases are essential enzymes for all living organisms and important
targets for anticancer drugs and antibiotics. Although DNA topoisomerases have been studied
extensively, steady-state kinetics has not been systematically investigated because of the lack of an
appropriate assay. Previously, we demonstrated that newly synthesized, ﬂuorescently labeled plasmids
pAB1_FL905 and pAB1_FL924 can be used to study DNA topoisomerase-catalyzed reactions by
ﬂuorescence resonance energy transfer (FRET) or supercoiling-dependent ﬂuorescence quenching
(SDFQ). With the FRET or SDFQ method, we performed steady-state kinetic studies for six diﬀerent
DNA topoisomerases including two type IA enzymes (Escherichia coli and Mycobacterium smegmatis
DNA topoisomerase I), two type IB enzymes (human and variola DNA topoisomerase I), and two
type IIA enzymes (E. coli DNA gyrase and human DNA topoisomerase IIα). Our results show that all DNA topoisomerases
follow the classical Michaelis−Menten kinetics and have unique steady-state kinetic parameters, KM, Vmax, and kcat. We found
that kcat for all topoisomerases are rather low and that such low values may stem from the tight binding of topoisomerases to
DNA. Additionally, we conﬁrmed that novobiocin is a competitive inhibitor for adenosine 5′-triphosphate binding to E. coli
DNA gyrase, demonstrating the utility of our assay for studying topoisomerase inhibitors.

■

nick or double-stranded break during catalysis.1 Each family is
further divided into diﬀerent subfamilies depending on
catalytic mechanisms.1,4 Type I enzymes cleave only one
strand of the DNA templates, while type II enzymes transiently
cleave both strands. During catalysis, type IA DNA topoisomerases (bacterial DNA topoisomerases I and III) link to
the 5′-phosphate. In contrast, type IB topoisomerases (human
topoisomerase I and poxvirus DNA topoisomerase I) link to
the 3′-phosphate of DNA.1,4 Although most DNA topoisomerases can relax (−) and/or (+) DNA supercoiling,1,4
bacterial DNA gyrase is the only enzyme that can actively
introduce (−) DNA supercoiling to its DNA substrates.1,4
One major assay for DNA topoisomerase activity is gel
electrophoresis.16,17 Although gel electrophoresis is quick and
convenient for resolving topoisomers of closed circular plasmid
DNA molecules,16,17 it is less suitable for probing kinetics
because gel electrophoresis cannot readily provide quantitative
analysis of DNA supercoiling in real time. More recently,

INTRODUCTION
DNA topoisomerases are enzymes that catalyze DNA
structural alterations that include relaxation of positively and
negatively supercoiled DNA and resolution of DNA knots and
catenanes.1−4 These enzymes create transient DNA breaks to
catalyze these changes in DNA topology.1−4 Because
topological issues are intrinsic to double-stranded DNA,5,6
DNA topoisomerases are critical for DNA replication,
transcription, recombination, and maintenance of the
chromosome structure.7−9 DNA topoisomerases are important
targets for anti-bacterial agents as well as anti-cancer drugs.10,11
Human topoisomerases I and II are targets of clinically
important anticancer drugs, such as topotecan10,12 and
doxorubicin.10 Bacterial DNA gyrase and Topo IV (another
type II enzyme) are the targets of ﬂuoroquinolones, such as
ciproﬂoxacin, which are critically important antibiotics.13−15
Bacterial topoisomerases continue to be useful targets for the
discovery of novel antibacterial drugs that could avoid cross
resistance with current antibiotics to counter the serious global
health problem of multidrug-resistant bacterial pathogens.
DNA topoisomerases are classiﬁed into type I and II families
according to whether they make a transient single-stranded
© 2019 American Chemical Society
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generate rx pAB1_FL905 or pAB1_FL924, 25 000 units of T4
DNA ligase were added in the presence of 10 mM of
dithiothreitol (DTT) and 2 mM of ATP (ﬁnal concentrations).
The reaction mixtures were incubated at 37 °C for 60 min to
seal the nicks, thereby yielding the rx pAB1_FL905 or
pAB1_FL924. T4 DNA polymerase (750 units) and dNTPs
(100 μM) were added to the ligation mixture to increase the
yield of the rx pAB1_FL905 or pAB1_FL924. After the
ligation step, 5000 units of T5 exonuclease were added into the
reaction mixture at 37 °C for 60 min to digest the nicked pAB1
and oligomer FL905 or FL924. The rx pAB1_FL905 or
pAB1_FL924 sample was extracted with 20 mL of phenol,
precipitated with isopropanol, washed once with 70% ethanol,
and dialyzed against a large excess of 1× TE buﬀer solution (10
mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), pH 8.0). To generate sc pAB1_FL905 or
pAB1_FL924, the ligation reaction was carried out in the
presence of 25 μM of ethidium bromide (EB). The other steps
are the same as the synthesis of rx pAB1_FL905 or
pAB1_FL924. The sc pAB1_FL905 or pAB1_FL924 sample
was extracted with 20 mL of phenol, precipitated with
isopropanol, washed once with 70% ethanol, and dialyzed
against a large excess of 1× TE buﬀer solution.
Fluorescence Spectroscopy. Fluorescence measurements
were performed using a Horiba FluoroMax-3 spectroﬂuorimeter with an excitation wavelength of 494 nm or a Biotek
Synergy H1 Hybrid Plate Reader with an excitation wavelength
of 482 nm where plasmid pAB1_FL905 was used. Alternatively, ﬂuorescence measurements were performed using a
homemade spectroﬂuorimeter with a 532 nm laser for the
excitation light source where pAB1_FL924 was used due to
the fact that the ﬂuorophore TAMRA of pAB1_FL924 was
stable under this condition.
DNA Supercoiling Density Determination. sc
pAB1_FL924 (4.6 μg) was relaxed by variola DNA
topoisomerase I in the presence of various concentrations of
EB at 37 °C in 1× CutSmart buﬀer for 1 h. Subsequently, the
relaxation reaction was stopped by addition of an equal volume
of phenol. The reaction mixtures were extracted one more time
with phenol (a total of 2 times of phenol extraction) and
dialyzed against 1 L of 10 mM Tris-HCl, pH 8.0 twice
overnight. The topological status of each DNA sample was
analyzed by electrophoresis in a 1% agarose gel in 1× TAE
buﬀer [40 mM Tris-acetate (pH 7.8) and 1 mM EDTA]
containing diﬀerent concentrations of chloroquine. After
electrophoresis, agarose gels were stained with EB, destained,
and photographed under UV light. The DNA linking number
change (ΔLk) was determined by analyzing the distributions
of the topoisomers, and the supercoiling density (σ) was
calculated as follows

single-molecule techniques, such as magnetic tweezers, have
been used to analyze mechanisms of DNA topoisomerasescatalyzed supercoiling/relaxation reactions.18−21 Indeed, these
elegant techniques provided mechanistic insights into various
DNA topoisomerase-catalyzed supercoiling/relaxation reactions;22−29 however, DNA molecules must be physically linked
onto solid surfaces.18,30 It is also not straightforward to derive
steady-state kinetic parameters, such as KM and kcat, from these
studies. Additionally, constraint onto magnetic beads could
inﬂuence diﬀusion or other aspects of radial DNA access of a
topoisomerase before, during, or after the breaking/resealing
reaction.18,30
Recently, we synthesized a type of unique ﬂuorescently
labeled DNA molecules that can be used to study DNA
topoisomerases by ﬂuorescence resonance energy transfer
(FRET) or supercoiling-dependent ﬂuorescence quenching
(SDFQ).31 This SDFQ method stems from the fact that
alternating adenine−thymine sequences (AT)n in the closed
circular plasmids undergo very rapid cruciform formation/
deformation depending on the supercoiling density of the
plasmids.32,33 A pair of ﬂuorophore−quencher were inserted in
the (AT)n sequence, so that the distance between the
ﬂuorophore and quencher is dramatically changed when the
plasmids adopt supercoiled (sc) or relaxed (rx) status.31 As a
result, the ﬂuorescence intensity of the plasmids is also greatly
changed upon supercoiling transition.31 We demonstrated that
these DNA molecules are excellent tools to examine
relaxation/supercoiling kinetics of DNA topoisomerases and
can be conﬁgured into rapid and eﬃcient high-throughput
screening assays to identify topoisomerase inhibitors.31 In this
work, we report an improved procedure to rapidly and
eﬃciently synthesize and purify ﬂuorescently labeled plasmid
DNA molecules. Using the SDFQ assays, we ﬁnd that all 6
DNA topoisomerases examined show characteristics of
classical Michaelis−Menten kinetics. We also demonstrate
that novobiocin is a competitive inhibitor for adenosine 5′triphosphate (ATP) binding to Escherichia coli DNA gyrase.

■

MATERIALS AND METHODS
Materials. Restriction enzyme Nt.BbvCI, T4 DNA
polymerase, T5 exonuclease, and T4 DNA ligase were
purchased from New England Biolabs (Beverly, MA, USA).
E. coli DNA topoisomerase I, E. coli DNA gyrase,
Mycobacterium smegmatis DNA topoisomerase I, variola DNA
topoisomerase I, human topoisomerase I, and human
topoisomerase IIα were puriﬁed as described previously.34−37
Ethidium bromide, buﬀer-saturated phenol, and isopropanol
were purchased from Thermo Fisher Scientiﬁc, Inc. The
synthetic oligonucleotides FL905 and FL924 were purchased
from MWG-Biotech, Inc. (Huntsville, AL) and were described
previously.31 Plasmid pAB1 was described previously31 and
puriﬁed using commercial plasmid puriﬁcation kits obtained
from QIAGEN, Inc. (Valencia, CA).
Synthesis of rx and sc pAB1_FL905 and pAB1_FL924.
The preparation of rx and sc pAB1_FL905 and pAB1_FL924
was described previously31 with some modiﬁcations. Brieﬂy, 1
mg of pAB1 (∼570 pmol) was digested by 2500 units of
Nt.BbvCI in 20 mL of 1× CutSmart buﬀer for 1 h at 37 °C.
After the digestion, 8000 pmol of phosphorylated FL905 or
FL924 was added into the reaction mixture. The reaction
mixture was incubated at 90 °C in a 4 L water bath for 2 min
and then cooled down to room temperature in the water bath
(∼4−5 h; usually this step was carried out overnight). To

ΔLk
Lk − Lk0
=
(1)
Lk0
Lk0
0
where Lk and Lk represent the DNA linking number for the
relaxed and the supercoiled DNA, respectively.
The ﬂuorescence intensity of these DNA samples was
measured by using a microplate reader with λex = 550 nm and
λem = 580 nm. DNA concentration was determined by UV
absorbance at 260 nm using a Cary 50 spectrophotometer.
Steady-State Kinetic Measurements. All steady-state
kinetic measurements were performed in 60 μL of a buﬀer
solution containing either sc pAB1_FL905 (pAB1_FL924) or
rx pAB1_FL905 (pAB1_FL924). CutSmart buﬀer [1× is 50
σ=
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mM KAc, 20 mM Tris-Ac, 10 mM Mg(AC)2, 100 μg/mL
bovine serum albumin (BSA), pH 7.9] was used for E. coli
DNA topoisomerase I, M. smegmatis DNA topoisomerase I,
and variola DNA topoisomerase I. Human Top1 buﬀer (1× is
10 mM Tris-Cl, pH 7.9, 150 mM NaCl, 0.1% BSA, 0.1 mM
spermidine, 5% glycerol) was used for human DNA
topoisomerase I. Human Top2 buﬀer (1× is 50 mM TriHCl, pH 8, 100 mM KCl, 1 mM EDTA, 8 mM MgCl2, 35 mM
β-mercaptoethanol, 0.5 mg/mL BSA, and 2 mM ATP or
indicated in the assay) was used for human DNA topoisomerase II. DNA gyrase buﬀer (1× is 35 mM Tris-HCl, pH 7.5, 24
mM KCl, 4 mM MgCl2, 2 mM DTT, 5 mM spermidine, 0.1
mg/mL BSA, 6.5% glycerol, and 1.75 mM ATP or indicated in
the assay) was used for E. coli DNA gyrase. Kinetic reaction
mixtures were assembled on ice (without enzyme) and
equilibrated to 37 °C usually for 5 min (in a cuvette inside
the spectroﬂuorimeter). Then, one of DNA topoisomerases
was added directly to the cuvette and mixed with other
components of reaction mixtures by pipetting three times. The
ﬂuorescence intensities of the reaction mixture at 521 nm (for
pAB1_FL905) or at 582 nm (for pAB1_FL924) were recorded
every 5 s. The initial velocity of the reactions was calculated
from linear-ﬁtting of the ﬁrst 5−10 data points. The steadystate kinetic parameters KM, Vmax, and kcat were obtained by
ﬁtting the Michaelis−Menten equation
V0 = Vmax

kcat =

[S]
KM + [S]

Vmax
[E]

Figure 1. Rapid and eﬃcient procedure to produce rx or sc
ﬂuorescently labeled plasmid pAB1_FL905. The experimental
procedure was described under the Materials and Methods.
Abbreviations: T4 DNAP, T4 DNA polymerase; DNA ligase, T4
DNA ligase; sc, supercoiled; nk, nicked, rx, relaxed.

lanes 1 and 2 with lane 4, and also lanes 5 and 6 with lane 8 of
Figure 2A). We also found that T4 DNA polymerase could
increase the yield of the labeled products (compare lane 1 with
lane 2 and lane 5 with lane 6 of Figure 2A). A possible reason
is that T4 DNA polymerase repaired some damaged DNA
templates during the nicking reaction. Additionally, 2 times of
phenol extraction removed most of the digested labeled
oligomers FL905 and FL924 (Figure 2A: compare lanes 1 and
2 with lanes 3 and 4; also compare lanes 5 and 6 with lanes 7
and 8). After isopropanol precipitation and dialysis steps, the
ﬂuorescently labeled plasmids pAB1_FL905 and pAB1_FL924
are free of the labeled oligomers and nicked or gapped pAB1.
To generate sc pAB1_FL905 or pAB1_FL924, 25 μM of EB
was added directly into the ligation reactions. We found that
EB did not signiﬁcantly aﬀect ligation reactions (Figure S1).
T5 exonuclease was able to remove nicked and gapped pAB1,
and also oligomers FL905 and FL924 (Figure 2A). With this
new method, we were capable of synthesizing milligrams of rx
or sc pAB1_FL905 and pAB1_FL924 in 3−4 days with high
yields.
In order to establish the relationship between the
ﬂuorescence intensity and the supercoiling density (σ) of
these ﬂuorescently labeled plasmids, we relaxed sc
pAB1_FL924 in the presence of increasing concentrations of
EB using variola DNA topoisomerase I. After removing EB by
phenol extraction and extensive dialysis, the ﬂuorescence
intensity of these DNA samples was measured and σ was
determined.39 Figure 2B−E shows our results. As expected, the
ﬂuorescence intensity was dependent on σ. When σ of
pAB1_FL924 ≤ −0.04 with a ΔLk ≤ −11, the ﬂuorescence
intensity reached the minimum. This is consistent with
previous results showing that the AT cruciform/hairpin was
fully formed at σ ≤ −0.04.40 As a result, the ﬂuorescence was
signiﬁcantly quenched (Figure 2B). At σ ≥ −0.02 with ΔLk ≥
−5, the hairpin structure disappeared and the ﬂuorescence
intensity increased sharply (Figure 2C). The supercoilingdependent ﬂuorescence transition supports that these ﬂuorescently labeled plasmids can be used to study kinetics of
diﬀerent DNA topoisomerases.
Steady-State Kinetics of Type I DNA Topoisomerases.
With rx or sc pAB1_FL905 and pAB1_FL924, we carried out
steady-state kinetic studies for 6 diﬀerent DNA topo-

(2)

(3)

where V0, [S], KM, Vmax, [E], and kcat represent the initial
velocity, substrate concentration, Michaelis constant, maximum velocity, enzyme concentration, and turn-over number,
respectively.

■

RESULTS AND DISCUSSION
A rapid and eﬃcient procedure to synthesize and
purify ﬂuorescently labeled plasmid DNA molecules.
Recently, we reported the synthesis of a type of unique
ﬂuorescently labeled plasmid DNA molecules that can be used
to study DNA topology and topoisomerases by FRET or
SDFQ.31 Although the synthesis yield of the ﬂuorescently
labeled plasmid DNA molecules was high, agarose gel
electrophoresis or CsCl−EB ultracentrifugation banding had
to be used to purify the labeled products from unlabeled
nicked DNA, the oligomer, and ATP.31 Both puriﬁcation
methods have unavoidable disadvantages. Speciﬁcally, gels are
not suited for purifying mg quantities of plasmid DNA, and
although CsCl−EB ultracentrifugation banding is capable of
purifying the labeled products in the milligram range, it is a
lengthy, expensive, and labor-intensive procedure. Additionally,
∼20% products may be lost during this puriﬁcation procedure
and handling circular DNA in the presence of EB causes
signiﬁcant nicking of the substrate DNA. Therefore, it was
desirable to develop a method to avoid these two laborintensive puriﬁcation methods. We developed a simple and
eﬃcient procedure to synthesize and purify ﬂuorescently
labeled rx and sc plasmid DNA molecules (Figure 1). We used
T5 exonuclease to digest nicked and gapped plasmids, and also
oligomers FL905 and FL924 because T5 exonuclease cannot
digest either rx and sc plasmid DNA molecules38 (compare
18415
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Figure 3. Steady-state kinetics of E. coli DNA topoisomerase I. (A)
Proposed reaction scheme for the relaxation reaction catalyzed by E.
coli DNA topoisomerase I. (B) Time courses of E. coli DNA
topoisomerase I-catalyzed DNA relaxation reactions monitored by
ﬂuorescence intensity change. For the relaxation reaction, 60 μL of 1×
CutSmart buﬀer (50 mM KAc, 20 mM Tris-Ac, 10 mM Mg(AC)2,
100 μg/mL BSA, pH 7.9) containing diﬀerent concentrations of sc
pAB1_FL905 was prepared and equilibrated to 37 °C, and 17 nM of
E. coli DNA topoisomerase I was used to relax the sc pAB1_FL905.
The ﬂuorescence intensity at λem = 521 nm was monitored with λex =
494 nm using a Horiba FluoroMax-3 spectroﬂuorimeter. (C) Initial
velocities of relaxation reaction were calculated from (B), plotted
against the substrate (pAB1_FL905) concentration, and ﬁtted into
the classical Michaelis−Menten equation to determine KM, Vmax, and
kcat. (D) Time courses of E. coli DNA topoisomerase I-catalyzed DNA
relaxation reactions monitored by 1% agarose gel electrophoresis; 465
μL of 1× CutSmart buﬀer (50 mM KAc, 20 mM Tris-Ac, 10 mM
Mg(AC)2, 100 μg/mL BSA, pH 7.9) containing 2.13 nM of sc
pAB1_FL905 was prepared and equilibrated to 37 °C, and 17 nM of
E. coli DNA topoisomerase I was used to relax the sc pAB1_FL905.
The reactions were stopped by adding 20 mM EDTA and 0.1% SDS
into the reaction mixtures. Lanes 1−7 represent DNA samples from 0,
30, 60, 120, 300, 450, and 600 s of the relaxation assay, respectively. rx
and sc represent relaxed and supercoiled DNA molecules,
respectively.

Figure 2. (A) Eﬀects of diﬀerent enzymes on the production of rx and
sc pAB1_FL905. rx (lanes 1−4) and sc (lanes 5−8) pAB1_FL905
were generated according to Figure 1 and also as described in
“Materials and Methods.” The DNA molecules were isolated and
subjected to 1% agarose gel electrophoresis in 1× TAE buﬀer.
Symbols and abbreviations: T4 DNAL, T4 DNA ligase; T4 DNAP,
T4 DNA polymerase; T5 exo, T5 exonuclease; nk, nicked plasmid; sc,
supercoiled plasmid; rx, relaxed plasmids; FL905, oligomer FL905.
Lane 9 is the NEB 1 kb DNA ladder. (B) Fluorescence spectra of sc
(σ = −0.06; dotted line) and rx (σ = 0; solid line) of pAB1_FL924
with λex = 532 nm. (C) Fluorescence intensity of pAB1_FL924 is
dependent of supercoiling density (σ). DNA topoisomeras with a
mean ΔLk were generated as described under Materials and Methods
and used here. The ﬂuorescence intensity of the same concentration
of pAB1_FL924 samples was measured using a microplate reader with
λex = 550 nm and λem = 580 nm. (D,E) Analysis of DNA topoisomers
using 1% agarose gel electrophoreses in the absence (D) and presence
of 2.5 μg/mL chloroquine (E) to determine the supercoiling density
of diﬀerent pAB1_FL924 samples. Lanes 1 to 9 are DNA samples
relaxed by variola DNA topoisomerase I in the presence of 0, 0.5, 1,
1.5, 2, 2.5, 3.75, 5, and 7.5 μM of EB, respectively. Lanes 10 and 11
are supercoiled and relaxed pAB1, respectively.

that reached plateau within 200−300 s (Figure 3B). Initial
velocities were calculated from these time courses and
successfully ﬁtted to the Michaelis−Menten equation to yield
a KM of 1.2 ± 0.3 nM, Vmax of 50 ± 4 pM/s, and kcat of 3.0 ×
10−3 s−1. These values are lower than those that we obtained
from agarose gel electrophoresis published previously.34
Possible reasons for this disparity include the following: (1)
gel electrophoresis is not as quantitative for analyzing the
kinetics of DNA topoisomerases. For example, the disappearance of the “most sc species” used in the agarose-gel based
assays may not represent the real initial velocity of E. coli DNA
topoisomerase I because the 1% agarose gels in the absence of
chloroquine cannot diﬀerentiate the initial, less sc DNA
products from the “most sc species”; (2) a diﬀerent plasmid
DNA template, that is, pXX6 (4483 bp) was used in our
previous studies and is signiﬁcantly larger than pAB1_FL905
used here; and (3) we used more E. coli DNA topoisomerase I
in the current studies than in the previous studies34 (17 vs 8
nM). The low turnover number (kcat, 3.0 × 10−3 s−1) suggests
that E. coli DNA topoisomerase I is a “slow” enzyme. It should
be noted however that the kcat values determined here
represent the whole plasmid molecule involving multiple
catalytic cycles along with the dissociation rate constant as the

isomerases. The ﬁrst DNA topoisomerase we examined is E.
coli DNA topoisomerase I, a 96 kDa monomeric type IA
topoisomerase.1 We kept E. coli DNA topoisomerase I
concentration at 17 nM and varied pAB1_FL905’s concentration from 0.36 to 6.39 nM (Figure 3). This condition is
consistent with previously published conditions for testing E.
coli topoisomerase I’s activity using agarose gel electrophoresis.34,41 Note that plasmid pAB1 is much larger than E.
coli DNA topoisomerase I (1800 kDa vs 96 kDa) and sc
pAB1_FL905 has ∼20 (−) supercoils. Considering the fact
that multiple E. coli DNA topoisomerase I can bind and
remove (−) supercoils from each pAB1_FL905, our testing
conditions should meet the requirements for steady-state
kinetics. Nevertheless, addition of E. coli DNA topoisomerase I
into a solution containing sc pAB1_FL905 caused a rapid
increase of ﬂuorescence intensity of the solution at 521 nm
18416
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enzyme is released from relaxed DNA products. We also
carried out a time course of the relaxation reaction of E. coli
DNA topoisomerase I using agarose gel electrophoresis
(Figure 3D). At 300 s, all pAB1_FL905 is fully relaxed,
which is consistent with our ﬂuorescence results.
Previous studies showed that high salt concentrations
inhibited the relaxation activities of E. coli DNA topoisomerase
I and also changed the ﬁnal topological status of the relaxed
topoisomers.42 Here, we performed kinetic studies of E. coli
topoisomerase I using plasmid pAB1_FL924 in two diﬀerent
solution conditions, 1× CutSmart buﬀer and 1× CutSmart
buﬀer plus 100 mM NaCl. Figure S2 shows the results. Indeed,
high salt concentration decreased the ﬂuorescence intensity of
the ﬁnal DNA topoisomers, presumably because of the
topological status diﬀerence of the ﬁnal relaxed topoisomers
(Figure S2A), and also inhibited the relaxation activities of E.
coli DNA topoisomerase I (Figure S2B). After ﬁtting our
kinetic data to the Michaelis−Menten equation, we obtained
the following kinetic parameters: KM of 1.2 ± 0.2 nM, Vmax of
51 ± 4 pM/s, and kcat of 3.0 × 10−3 s−1 for 1× CutSmart buﬀer
and KM of 1.5 ± 0.2 nM, Vmax of 40 ± 3 pM/s, and kcat of 2.3 ×
10−3 s−1 for 1× CutSmart buﬀer plus 100 mM NaCl. The KM
value does not change signiﬁcantly, while Vmax decreases in the
high salt buﬀer condition, which is similar to the eﬀect of a
noncompetitive inhibitor of the enzyme.
M. smegmatis DNA topoisomerase I, a 110 kDa monomeric
type IA topoisomerase,43 was also examined. It is the only type
IA DNA topoisomerase of M. smegmatis, essential for this
bacterium,44,45 and a validated target for antibiotic discovery.13,44,46 In DNA relaxation time courses, we kept M.
smegmatis DNA enzyme ﬁxed at 13.3 nM and varied DNA
concentrations from 0.37 to 4.41 nM (Figure S3). Similar to E.
coli DNA topoisomerase I, M. smegmatis DNA topoisomerase I
was able to fully relax sc pAB1_FL905 (Figure S3A,D). Initial
velocities were calculated from these time courses and
successfully ﬁtted to the Michaelis−Menten equation to yield
a KM of 4.3 ± 3.0 nM, Vmax of 130 ± 5 pM/s, and kcat of 9.8 ×
10−3 s−1. The KM value is slighter higher than that of E. coli
DNA topoisomerase I and may be due to the divergent Cterminal domains.47 Again, the turnover number (kcat, 9.8 ×
10−3 s−1) is rather low indicating that M. smegmatis DNA
topoisomerase I is also a comparatively “slow” enzyme.
Additionally, two type IB DNA topoisomerases, variola and
human DNA topoisomerase I, were examined. Both enzymes
can relax (+) and (−) DNA supercoiling.1,48 Variola DNA
topoisomerase I is the smallest topoisomerase (314 aa residues,
∼36.6 kDa; variola DNA topoisomerase I is similar to another
poxvirus vaccinia topoisomerase I except for 3 amino
acids48,49). Figure 4 shows the steady-state kinetics of variola
DNA topoisomerase I. The KM, Vmax, and kcat were determined
to be 2.4 ± 1.0 nM, 120 ± 23 pM/s, and 6.0 × 10−3 s−1,
respectively. Human topoisomerase I is a 90.7 kDa monomer
(765 aa residues)1 and an important anticancer drug target.50
Notably, topoisomerase I inhibitors irinotecan and topotecan,
derivatives of camptothecin, are highly eﬀective FDA approved
anticancer drugs.51 Interestingly, more recent studies showed
that human topoisomerase I relaxation activity is related to
autism spectrum disorder52 and inﬂammation.53 Figure 5
shows the results of steady-state kinetic studies of human DNA
topoisomerase I. Apparently, it follows the classic Michaelis−
Menten kinetics. The KM, Vmax, and kcat were determined to be
2.7 ± 1.00 nM, 31 ± 5 pM/s, and 1.2 × 10−3 s−1, respectively.

Figure 4. Steady-state kinetics of variola DNA topoisomerase I. (A)
Proposed reaction scheme for the relaxation reaction catalyzed by
variola DNA topoisomerase I. (B) Time courses of variola DNA
topoisomerase I-catalyzed DNA relaxation reactions monitored by
ﬂuorescence intensity change. For the relaxation reaction, 60 μL of 1×
CutSmart buﬀer (50 mM KAc, 20 mM Tris-Ac, 10 mM Mg(AC)2,
100 μg/mL BSA, pH 7.9) containing diﬀerent concentrations of sc
pAB1_FL905 was prepared and equilibrated to 37 °C, and 20 nM of
variola DNA topoisomerase I was used to relax the sc pAB1_FL905.
The ﬂuorescence intensity at λem = 521 nm was monitored with λex =
494 nm using a Horiba FluoroMax-3 spectroﬂuorimeter. (C) Initial
velocities of relaxation reaction were calculated from (B), plotted
against the substrate (pAB1_FL905) concentration, and ﬁtted into
the classical Michaelis−Menten equation to determine KM, Vmax, and
kcat. (D) Time courses of variola DNA topoisomerase I-catalyzed
DNA relaxation reactions monitored by 1% agarose gel electrophoresis; 450 μL of 1× CutSmart buﬀer (50 mM KAc, 20 mM TrisAc, 10 mM Mg(AC)2, 100 μg/mL BSA, pH 7.9) containing 2.2 nM of
sc pAB1_FL905 was prepared and equilibrated to 37 °C, and 20 nM
of variola DNA topoisomerase I was used to relax the sc
pAB1_FL905. The reactions were stopped by adding 20 mM
EDTA and 0.1% SDS into the reaction mixtures. Lanes 1−7 represent
DNA samples from 0, 30, 60, 120, 300, 450, and 600 s of the
relaxation assay, respectively. rx and sc represent relaxed and
supercoiled DNA molecules, respectively.

Steady-State Kinetics of Type IIA DNA Topoisomerases. Next, we studied the steady-state kinetics of the
type IIA DNA topoisomerases, E. coli DNA gyrase, and human
DNA topoisomerase IIα. Both enzymes require ATP for
catalytic activity.1 E. coli DNA gyrase is a tetrameric protein
and contains two diﬀerent kinds of subunits, gyrA and gyrB
that form an active A2B2 complex.1 DNA gyrase is the only
known DNA topoisomerase that actively introduces (−)
supercoils in DNA substrates under normal reaction conditions
and therefore requires hydrolysis of ATP.1−3 DNA gyrase only
exists in bacteria, is an essential enzyme,54−56 and could be
used to identify inhibitors without signiﬁcantly aﬀecting host
human enzymes.10,57 Figures 6 and S4 show our kinetic results.
Addition of DNA gyrase to solutions containing rx
pAB1_FL905 resulted in a signiﬁcant decrease of the
ﬂuorescence intensity of the solution at 521 nm that reached
the plateau within 300−400 s (Figure 6B) and a complete (−)
supercoiling of the rx pAB1_FL905 (Figure 6C). Because E.
coli gyrase has two substrates, rx DNA pAB1_FL905 and ATP,
we determined the pseudo ﬁrst-order kinetics for both
substrates by ﬁtting the initial velocity results to the
Michaelis−Menten equation (Figure 6D,E). For rx DNA
pAB1_FL905, we kept the ATP concentration at 1.75 mM and
18417

DOI: 10.1021/acsomega.9b02676
ACS Omega 2019, 4, 18413−18422

ACS Omega

Article

Figure 5. Steady-state kinetics of human DNA topoisomerase I. (A)
Proposed reaction scheme for the relaxation reaction catalyzed by
human DNA topoisomerase I. (B) Time courses of human DNA
topoisomerase I-catalyzed DNA relaxation reactions monitored by
ﬂuorescence intensity change. For the relaxation reaction, 60 μL of 1×
human Top1 buﬀer (10 mM Tris-Cl, pH 7.9, 150 mM NaCl, 0.1%
BSA, 0.1 mM spermidine, 5% glycerol) containing diﬀerent
concentrations of sc pAB1_FL905 was prepared and equilibrated to
37 °C, and 25 nM of human DNA topoisomerase I was used to relax
the sc pAB1_FL905. The ﬂuorescence intensity at λem = 521 nm was
monitored using a Biotek Synergy H1 Hybrid Plate Reader with an
excitation wavelength of 482 nm. (C) Initial velocities of relaxation
reaction were calculated from (B), plotted against the substrate
(pAB1_FL905) concentration, and ﬁtted into the classical Michaelis−
Menten equation to determine KM, Vmax, and kcat.

Figure 6. Steady-state kinetics of E. coli DNA gyrase. (A) Proposed
reaction scheme for the supercoiling reaction catalyzed by E. coli DNA
gyrase. The reaction includes two substrates: ATP and DNA
(pAB1_FL905). (B) Time courses of E. coli DNA gyrase-catalyzed
DNA supercoiling reactions monitored by ﬂuorescence intensity
change. For the supercoiling reaction, 60 μL of 1× DNA gyrase buﬀer
(35 mM Tris-HCl, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.75 mM
ATP, 5 mM spermidine, 0.1 mg/mL BSA, 6.5% glycerol, pH 7.5)
containing diﬀerent concentrations of rx pAB1_FL905 was prepared
and equilibrated to 37 °C, and 44.6 nM of E. coli DNA gyrase was
used to supercoil the rx pAB1_FL905. The ﬂuorescence intensity at
λem = 521 nm was monitored with λex = 494 nm using a Horiba
FluoroMax-3 spectroﬂuorimeter. (C) Time courses of E. coli DNA
gyrase-catalyzed DNA supercoiling reactions monitored by 1%
agarose gel electrophoresis. 384 μL of 1× DNA gyrase buﬀer
containing 7.2 nM of rx pAB1_FL905 was prepared and equilibrated
to 37 °C, and 44.6 nM of E. coli DNA gyrase was used to supercoil the
rx pAB1_FL905. The reactions were stopped by adding 20 mM
EDTA and 0.1% SDS into the reaction mixtures. Lanes 1−7 represent
DNA samples from 0, 30, 60, 120, 300, 450, and 600 s of the
supercoiling assay, respectively. rx and sc represent relaxed and
supercoiled DNA molecules, respectively. (D) Initial velocities of
supercoiling reaction were calculated from (B), plotted against the
substrate (sc pAB1_FL905) concentration, and ﬁtted into the classical
Michaelis−Menten equation to determine KM, Vmax, and kcat for the
DNA substrate (rx pAB1_FL905). (E) Initial velocities of supercoiling reaction were plotted against ATP concentration and ﬁtted
into the classical Michaelis−Menten equation to determine KM and
Vmax for ATP.

varied DNA concentration from 0.75 to 7.2 nM to yield a KM,
Vmax, and kcat of 2.7 ± 0.2 nM, 50 ± 2 pM/s, and 1.1 × 10−3
s−1, respectively. For ATP, we kept the concentration of rx
pAB1_FL905 at 7.2 nM and varied the ATP concentration
from 0.1 mM to 2 mM to generate a KM and Vmax of 0.33 ±
0.14 mM and 50 ± 7 pM/s, respectively. The KM values of
DNA gyrase are consistent with previously published results
using ATPase assays58,59 and single-molecule techniques.60
Previously, it was demonstrated that novobiocin is a
competitive inhibitor of DNA gyrase to prevent ATP binding
to gyrase subunit B.61 In this study, we also performed kinetic
studies of E. coli DNA gyrase in the absence and presence of 60
nM of novobiocin. Figure 7 shows our results. As expected,
novobiocin signiﬁcantly inhibited the supercoiling reaction of
E. coli DNA gyrase (Figure 7A). Fitting of these kinetics to the
Michaelis−Menten equation produced the following kinetic
parameters: KM of 0.4 ± 0.1 mM and Vmax of 50 ± 3 pM/s in
the absence of novobiocin and KM of 2.4 ± 0.1 mM and Vmax
of 50 ± 2 pM/s in the presence of 60 nM novobiocin. Vmax is
identical while KM is signiﬁcantly higher in the presence of
novobiocin. This result demonstrates that novobiocin is a
competitive inhibitor of ATP for E. coli DNA gyrase. In the
Lineweaver−Burk or double-reciprocal plot, the intercept on
the y-axis of the plot of 1/V0 versus 1/[ATP] is the same in the
presence or absence of novobiocin showing that novobiocin
competes with ATP for its binding sites on E. coli DNA gyrase.
The Ki value was calculated to be 11.6 nM which is consistent
with the previous determination.61
Human DNA topoisomerase IIα is a homodimer with 1531
residues and 174 385 Da per monomer.1,62 It can relax both
(−) and (+) supercoiled DNA in the presence of ATP1 and
plays an essential role during mitosis and meiosis as a

decatenase.63 This enzyme is also a target of several important
anticancer drugs, including doxorubicin and etopside.10,64
Similar to DNA gyrase, human DNA topoisomerase IIα has
two substrates, sc plasmid DNA and ATP. Therefore, we
determined the pseudo ﬁrst order steady-state kinetic
parameters for both substrates (Figure S5). For sc DNA
pAB1_FL924, we kept the ATP concentration at 2 mM and
varied DNA concentration from 1.3 to 8 nM to yield KM, Vmax,
and kcat of 5.7 ± 1.5 nM, 187 ± 25 pM/s, and 6.7 × 10−3 s−1,
respectively. For ATP, we kept the concentration of sc
pAB1_FL924 at 4 nM and varied the ATP concentration from
0.025 mM to 2 mM to generate a KM and Vmax of 0.22 ± 0.06
mM and 99 ± 8 pM/s, respectively. The KM value of human
DNA topoisomerase IIα is consistent with previously
published results using ATPase assays65−68 and singlemolecule techniques22 for human and other eukaryotic DNA
topoisomerase IIα.
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Figure 8. (A) Simpliﬁed reaction pathway for the classical Michaelis−
Menten enzyme kinetics. (B) Proposed kinetic pathway for DNA
topoisomerases. DNA topoisomerases may need to dissociate from
the DNA product before the next round of catalysis. koff represents the
oﬀ rate constant for DNA topoisomerases dissociating from the
product.

need to dissociate from the DNA product for the next round of
catalysis. If topoisomerases still tightly bind to their product,
koff should be low, which yields a low kcat. Indeed, the koff value
of E. coli DNA topoisomerase I was determined previously and
shown to be quite low69 (0.017−0.043 s−1). In other words,
the low values of kcat of E. coli DNA topoisomerase I stem from
its tight binding to DNA. Recently, it was reported that
Streptomyces coelicolor DNA topoisomerase I is a highly
processive enzymes and can relax ∼150 (−) supercoils in a
single burst in the single-molecule assay.70 Steady-state kinetic
parameters were also determined using a gel-based assay and
pUC1834 to yield a KM of 5.1 nM and a Vmax of 108 pM/s (6.5
nM/min).70 Because 5 nM of DNA topoisomerase I was used,
this produces a kcat of 2.2 × 10−2 s−1, comparable to kcat values
determined in this article (Table 1). Although the SDFQ
method provides quantitative measurements for kinetic studies
of DNA topoisomerases, we noticed some limitations for this
method. This assay cannot be used to measure relaxation of
(+) sc DNA. Additionally, this method only works in a relative
narrow range of σ, that is, −0.02 ≥ σ ≥ −0.04 and cannot be
used to study the transition of hypernegatively sc DNA to (−)
sc DNA with σ ≤ −0.04.
In conclusion, we developed a rapid and eﬃcient method to
generate rx and sc ﬂuorescently labeled plasmid DNA
molecules for DNA topoisomerases. Utilizing the ﬂuorescently
labeled rx and sc pAB1_FL905 and pAB1_FL924, we found
that all 6 DNA topoisomerases including type IA, IB, and IIA
topoisomerases follow the classical Michaelis−Menten kinetics.

Figure 7. Novobiocin is a competitive inhibitor of E. coli DNA gyrase
to prevent ATP binding. (A) Inhibition of E. coli DNA gyrase
catalyzed supercoiling reaction as a function of ATP. DNA
supercoiling reactions were performed as described in “Materials
and Methods” and also in the legend of Figure 6. The kinetic results
were ﬁtted to the classical Michaelis−Menten equation to yield KM,
Ki, and Vmax. (B) Lineweaver−Burk plot or double-reciprocal plot of
E. coli DNA gyrase in the absence or presence of novobiocin. Closed
circles and squares represent supercoiling reactions in the absence and
presence of 60 nM novobiocin, respectively.
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SUMMARY
Table 1 summarizes the steady-state kinetic parameters for 6
DNA topoisomerases that we examined in this study. The
Michaelis constants of these topoisomerases are all in the
nanomolar range. Because KM can be used to estimate the
strength of the enzyme substrate (ES) complex (Figure 8A),
low KM values indicate strong binding of topoisomerases to
DNA, which is consistent with previously published
results.34,69 Intriguingly, the kcat values of these 6 DNA
topoisomerases are all low (Table 1). To explain this, we are
considering a kinetic pathway for topoisomerases (Figure 8B).
The enzyme and substrate form an ES complex and become an
enzyme-product complex through an activation ES* state.
After relaxation or supercoiling steps, the topoisomerases may

Table 1. Steady-State Kinetic Parameters for DNA Topoisomerases
enzymea

subfamily type

KM (nM)

EcTopI

IA

MsTopI
vTopI
hTopI
EcGyrase
EcGyrasee (ATP, mM)

IA
IB
IB
IIA
IIA

hTopIIα
hTopIIαe (ATP, mM)

IIA
IIA

1.2 ± 0.3b
1.5 ± 0.2c
7.5 ± 2.2 (ref 34)d
4.3 ± 3.0
2.4 ± 1.0
2.7 ± 1.0
2.7 ± 0.2
0.33 ± 0.14
0.3 (refs 58 and 61)d
0.16 (ref 60)d
5.7 ± 1.5
0.2 ± 0.1
0.56 ± 0.17 (ref 65)d
0.5 ± 0.3 (ref 68)d

kcat (s−1)

Vmax (pM/s)
50
40
8.0
130
120
31
50
51

±
±
±
±
±
±
±
±

4b
3c
1.0 (ref 34)d
5
23
5
2
7

187 ± 25
99 ± 8

3.0
2.3
1.2
9.8
6.0
1.2
1.1

× 10−3b
× 10−3c
± 0.5 (ref 34)d
× 10−3
× 10−3
× 10−3
× 10−3

6.7 × 10−3

a

EcTopI, E. coli DNA topoisomerase I; MsTopI, M. smegmatis DNA topoisomerase I; vTopI, variola DNA topoisomerase I; hTopI, human
topoisomerase I; EcGyrase, E. coli DNA gyrase; hTopIIα, human DNA topoisomerase IIα. bThese kinetic parameters were determined in 1×
CutSmart buﬀer. cThese kinetic parameters were determined in 1× CutSmart buﬀer plus 100 mM NaCl. dThese values were determined in the
cited references. eThe concentration unit for KM of ATP is mM.
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We determined the steady-state kinetic parameters, that is, KM,
Vmax, and kcat, for these DNA topoisomerases. Using this
kinetic study, we also conﬁrmed that novobiocin is a
competitive inhibitor of DNA gyrase to prevent ATP binding.

■
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